Price rebates will continue to figure prominently in purchasing contracts between biopharmaceutical manufacturers and pharmacy benefit managers despite criticism that the practice creates a lack of pricing transparency and is not suited to high deductible health plans, Avalere Health President Dan Mendelson predicts.
PBMs negotiate rebates (retroactive price discounts) with manufacturers in return for market access. PBMs use them to foster competition and...






